Indexat a

Enllaç extern

Llicència i ús

Citacions

Altmetrics

Anàlisi d'autories institucional

Bernardo MAutor o coautorFlorez GAutor o coautorGarriga MAutor o coautorGoikolea JmAutor o coautor

Compartir

Clinical practice guideline on pharmacological and psychological management of adult patients with attention deficit and hyperactivity disorder and comorbid substance use

Publicat a:Adicciones. 34 (2): 168-178 - 2022-01-01 34(2), DOI: 10.20882/adicciones.1569

Autors: Cunill, Ruth; Castells, Xavier; Gonzalez-Pinto, Ana; Arrojo, Manuel; Bernardo, Miquel; Saiz, Pilar A; Florez, Gerardo; Torrens, Marta; Tirado-Munoz, Judit; Fonseca, Francia; Arranz, Belen; Garriga, Marina; Manuel Goikolea, Jose; Zorrilla, Inaki; Becona, Elisardo; Lopez, Ana; San, Luis

Afiliacions

Resum

Substantial evidence has confirmed the high comorbidity between Attention-Deficit/Hyperactivity Disorder (ADHD) and a substance use disorder (SUD). This review synthesizes the pharmacological and psychosocial interventions conducted in ADHD and SUDs, and provides clinical recommendations using the GRADE approach. Our results suggest: 1) In patients with ADHD and alcohol use, atomoxetine is recommended to reduce ADHD symptoms (weak recommendation) and alcohol craving (weak recommendation). 2) In patients with ADHD and cannabis use disorder, atomoxetine is recommended to improve ADHD symptoms (weak recommendation), not to reduce cannabis use (weak recommendation). 3) In patients with ADHD and cocaine use disorder, methylphenidate is not recommended to improve ADHD symptoms or to reduce cocaine use (weak recommendation). 4) In patients with ADHD and comorbid nicotine use disorder, methylphenidate is recommended to improve ADHD symptoms (weak recommendation). Psychoestimulants, such as methylphenidate or lisdexamfetamine dimesylate, are not recommended to reduce nicotine use (weak recommendation). 5) Regarding patients with ADHD and any SUD, the use of psychostimulants is recommended to improve ADHD symptoms (weak recommendation), not to reduce substance use (weak recommendation) or to improve retention to treatment (strong recommendation). In these patients, the use of atomoxetine is recommended to improve ADHD symptoms (weak recommendation), not to decrease substance use (weak recommendation) or to improve retention to treatment (strong recommendation). Atomoxetine and psychostimulants appear to be safe in patients with any SUD (strong recommendation). Our review suggests the need for more research in this area and for larger, multisite, randomized studies to provide more definite and conclusive evidence. © 2022, Edita Socidrogalcohol. All rights reserved.

Paraules clau